GLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images.

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set themselves apart in a competitive job market.

GLP-1 Drugs: Demand Surges in a Long-Established Market The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research.

GLP-1 receptor agonists have proven to be effective for weight loss but “we don’t know what the long-term outcomes are of targeting this risk factor . . . in terms of secondary prevention of atrial ...

In fact, about 1 in 8 Americans have taken a GLP-1 drug at some point in their life, according to KFF health. Drugs like Ozempic and Mounjaro are highly effective at curbing pounds.

GLP-1 drugs may also be useful in treating fatty liver disease and conditions ranging from asthma to chronic obstructive pulmonary disease, sleep apnea, osteoarthritis, depression, and eye disorders.

GLP-1 is a good example of how it’s not just what you eat that matters, it’s also how you eat it. The Mediterranean diet outperformed semaglutide drugs at lowering risk of cardiac events.

Fact checked by Nick Blackmer GLP-1 medications like Ozempic and Wegovy have become popular for helping people lose weight or manage diabetes—but the drugs are expensive.The cost of these ...

GLP-1 drugs like semaglutide and tirzepatide drive weight loss, but a new study finds they don't improve cardiovascular fitness and can trigger significant muscle loss. Experts urge pairing ...

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA set a cut-off date for this month on pharmacies that compound GLP-1 ...

1. Yousafzai O, Annie F, Rinehart S. GLP-1 receptor agonists and cardiovascular outcomes in patients with coronary outcomes in patients with coronary plaque: a real-world propensity-matched analysis.

Abandonment rates for patients approved for GLP-1 use were constant for 2021 (23.7%) and 2022 (23.4%). In 2023, the abandonment rate increased to 28.5% (Figure 4). This increase may be due to an ...